This report is concerned with neurofibromatosis type 1 (NF-1, 17q11.2) in south-western Ontario, an ethnically diverse population derived from multiple immigrations. The population incidence, prevalence, and mutation rates for this disease are similar in most racial groups of this population and are also comparable to earlier reports. NF-1 is one of the most common single gene disorders in this population. The occurrence of the disease is not affected by the birth order or sex of the transmitting parent. The severe manifestation of this disease is statistically related to paternal transmission. Five polymorphic DNA probes (pA1041, pE1HHH202, pTH1719, NF1, pEW206, pEW207) were evaluated in relation to segregation of NF-1 using appropriate restriction enzymes. The observed heterozygosity was found to be relatively high, ranging from 25% to 55% for all the probes on 17q and flanking the NF-1 gene. We recommend the use of pHHH202/pTH1719 and pEW206 in any linkage analysis for detection of the presence of the NF-1 mutation. For informative families the degree of certainty is as high as 99 5%. Some future modifications
may include the use of NF-1 exon specific probes and primers that remain to be evaluated for heterogeneity and heterozygosity among populations.
Neurofibromatosis type 1 (NF-1, von Recklinghausen disease) is one of the most common autosomal dominant disorders with a frequency of approximately 1/3000. Although NF-l-was first noted by Virchow in 1847 and described by von Recklinghausen in 1882, the clinical criteria for its diagnosis were only agreed by an NIH Consensus Panel in 1987. Today the diagnosis of the disease is based on two or more of the following features: six or more cafe au lait spots; two or more neurofibromas or one plexiform neurofibroma; freckling in the axillary or inguinal regions; optic glioma; two or more Lisch nodules; a distinct osseous lesion such as sphenoid dysplasia or thinning of the long bone cortex, with or without pseudoarthrosis; a first degree relative who meets the above criteria for NF-1.' The onset of the expression of NF-1 is age dependent and diagnosis is not always reliable in paediatric cases. Even in adults with familial NF-1 the expression of the disease is highly variable; not all affected subjects show all symptoms and when a given symptom is present in a number of subjects, the severity of the symptom varies greatly. The Blood samples (10 to 20 ml) were collected from all available family members (first and second degree relatives) of confirmed NF-i patients. They were used to establish permanent cell lines'5 and for the isolation of genomic DNA for restriction fragment analysis using five NF-i linked DNA probes on chromosome 17 . The permanent cell lines will be used in future research. We will be willing to consider any collaborative proposal from international researchers. The extraction of DNA from whole blood was performed using the guanidium hydrochloride and phenol/chloroform method modified from Jeanpierre'6 and Sambrook et al. '7 The DNA samples were digested with appropriate restriction enzymes and fragments separated on 0-8% or 1% agarose (Biorad Laboratories) gels. DNA fragments were then transferred to Zetaprobe nitrocellulose membrane (Biorad) using alkaline blotting '7 and covalently bound to the membrane by UV irradiation (320 nm for 15 minutes).
DNA PROBES
Five NF-i linked DNA probes were used (with a number of suitable restriction enzymes) to detect six different RFLPs. The probe-enzyme combinations used in this study are; pUC1041-PvuII, pEW206-MspI, pEW207-BglII and HindIII, pHHH202-RsaI, and pTH1719-BglII. Inserts of known size representing these probes were isolated electrophoretically in low melting point agarose (Seaplaque) and 25 to 50ng of insert were radiolabelled with 32P_ dCTP using the random hexanucleotide primers labelling system (Bethesda Research Labs). Radiolabelled probes were purified through Sephadex Nick-Columns (Pharmacia) and were found to have specific activities of 0 (2) , moderate (3), and severe (4) expression. These results were analysed with respect to the parental origin of the mutation. In our sub-sample of 65 patients (33 males and 32 females), 29 received the mutation from the mother and 36 from the father. In this group of patients, the mean severity score for the affected parents (2-15 (SD 0 64)) was not significantly different from the mean severity score of the offspring (1-89 (SD 0 66)) and there was no association between severity of expression in the parent and the offspring. It should be pointed out, however, that of the affected subjects who received the mutation from the mother, 75% showed minimal (1) symptoms and 8-3% had moderate (3) and severe (4) manifestations. The corresponding numbers for paternally transmitted mutations was 35-7% and 35-8% respectively. This distribution is significant (p > 0-01).
The evaluation of NF-1 linked RFLPs in the subset of our population analysed so far is summarised in the table in relation to estimates of polymorphic index and in comparison to other reported populations. It shows that the six probe-enzyme combinations are polymorphic in this population with site specific variable degree of heterozygosity. Of the five probes used in this study, two are located distal to the NF-1 gene (pEW206 and pEW207), while pHHH202 and pTH1719 are proximal to this locus on the q arm of chromosome 17. In contrast, pA1041 has been localised to the p arm near the centromere.21 The relative position and the estimated recombination fraction for these sites in relation to the NF-1 gene are also included in the table. Probes pHHH202/pTH1719 (located proximal to the NF-1 locus) show a recombination of 10% and pEW206 shows a recombination of less than 5% distally. Thus, this combination of markers could be used with a high degree of certainty if they were found to be informative in populations and families. This table also includes genetic parameters given as observed heterozygosity and allelic frequencies which are necessary to evaluate the usefulness of individual markers. The observed heterozygosity of this population is not comparable to other reports at all sites examined. For example, the heterozygosity detected by pHHH202-RsaI is 0 54 in our sample as compared to a range of 0-25 to 0-49 reported previously. On the other hand the heterozygosity generated by pEW207-BglII in this population is comparable to other estimates (table). These population specific patterns are also reflected in the allelic frequencies, as expected. The familial segregation of these markers was further used to calculate lod scores for each of the polymorphic sites in relation to the NF-1 mutation. These estimates (not given) conform to earlier reports and suggest that the region of chromosome 17q covered by the four probes represents a total of 0.15 recombination fraction flanking the NF-1 locus.
Discussion
Population studies on mendelian diseases are essential for evaluation of the nature and types of mutation(s) causing the disease, including explanations and hypotheses related to the frequency of the disease and a particular mutation. Such studies also allow evaluation of factors affecting severity and the impact of management or treatment protocols. Population studies are particularly relevant after the gene has been localised and cloned. The genotypic and phenotypic heterogeneity and distribution of mutation(s) across populations, an essential component in the understanding of genetic diseases, can only be obtained by population studies. The cloning of the gene for a defect does not allow 100% assurance in diagnosis and prediction, because of the nature of disease specific genetic heterogeneity; families may have unique mutations (for example, factor IX deficiency22), one predominant mutation (for example, cystic fibrosis23), or a single mutation in all cases (for example, sickle cell disease24). Thus the cloning and localisation of a gene does not necessarily permit direct detection of the molecular defect Genetic parameters for NF-1 linked DNA probes in familial neurofibromatosis type 1. on an individual basis. This has direct implications for genetic screening and prediction. This population study deals with genetic parameters of NF-1 in families in south-western Ontario, Canada, a genetically diverse population with much immigration. The results include familial segregation, pattem of expression, and molecular linkage. The linkage studies involve a number of closely linked DNA probes on chromosome 17. The results are informative in assessing the genetic heterogeneity of NF-1 in this population. Over the last year there have been major developments in NF-1 research including the recent discovery of the gene and part of its cDNA sequence. The predicted amino acid sequence of the resulting polypeptide appears to have been conserved throughout evolution. Although the exact function of the NF-1 gene is not known, the possibility of a role for this gene as a tumour suppressor has been suggested. 25 The availability of the gene sequence and relevant probes allows experiments on the biochemistry and cell biology of this gene and gene product in its normal and abnormal state. These probes are informative and useful in aspects of diagnosis, prediction, and population or family specific differences and similarities.
The results reported here support a number of recognised features of NF-1, including high frequency of the disease in the population, autosomal dominant pattern of inheritance, and no effect of sex, birth order, or parental age on transmission or expression. Also, a high proportion of patients in the population have no family history (accounted for by the high mutation rate) and there is no concentration of the disease in a particular racial group or founding population. The question of parental age effect has been addressed in a number of studies. Riccardi et aP6 found the paternal age for NF-1 patients to be 3-15 years higher and maternal age to be 1-39 years higher than unaffected controls in a much larger sample. This may account for the predominantly higher rate ofNF-1 mutation in the paternal genome as suggested by Jadayel et al."1 Although it was not possible to estimate the incidence or prevalence with any degree of accuracy, we feel that our case load and dataset (although incomplete) compare well with other estimates.6 To date, there is no evidence in our sample that one sex affected with NF-1 has a lower fitness than the other and the sex of an affected subject makes little or no difference to the possibility of transmission of the mutation to the next generation. The 
